Clinical trialNCT04724837CompletedPhase 2Interventional

Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)

SponsorAstraZenecaEnrollment542Chronic Kidney Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and dapagliflozin 10 mg as monotherapy in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73 m\^2, and urinary albumin to creatinine ratio (UACR) ≥ 150 mg/g and ≤ 5000 mg/g.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

David C Wheeler, MB ChB, MD, FRCP
Centre for Nephrology Royal Free Campus University College London Rowland Hill Street London NW3 2PF United Kingdom
Principal Investigator
clinicaltrials.gov ↗
Jamie P. Dwyer, M.D.
Nephrology Clinical Trials Center Nephrology and Hypertension Vanderbilt University Medical Center Nashville TN United States of America
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

164 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Research Site
Buenos Aires, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
Corrientes, Argentina
Research Site
Córdoba, Argentina
Research Site
Junín, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Mar del Plata, Argentina
Research Site
San Luis, Argentina
Research Site
San Miguel de Tucumán, Argentina
Research Site
Santa Fe, Argentina

Australia

Research Site
Adelaide, Australia
Research Site
Birtinya, Australia
Research Site
Elizabeth Vale, Australia
Research Site
Gosford, Australia
Research Site
Westmead, Australia

Brazil

Research Site
Botucatu, Brazil
Research Site
Campinas, Brazil
Research Site
Curitiba, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Santo André, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil

Bulgaria

Research Site
Gabrovo, Bulgaria
Research Site
Kozloduy, Bulgaria
Research Site
Montana, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Sliven, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Stara Zagora, Bulgaria

Canada

Research Site
St. John's, Newfoundland and Labrador, Canada
Research Site
London, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Waterloo, Ontario, Canada

Croatia

Research Site
Pula, Croatia
Research Site
Vinkovci, Croatia

Denmark

Research Site
Gentofte Municipality, Denmark

124 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dapagliflozin →PlaceboZibotentan

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Apr 2021
Primary completion: 1 Jun 2023
Completion: 1 Jun 2023
Last update posted: 30 Jul 2024
Registered enrollment: 542
Registry id: NCT04724837

Cross-registrations

EU-CTR / CTIS (EudraCT)2020-004101-32

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.